What's New in the Treatment of HER2 Positive Breast Cancer

In this brief presentation, Director of the Rena Rowan Breast Center Kevin Fox, MD, explains the function, significance and pathology of the human epidermal growth factor receptor 2 (HER2) gene in heritable breast cancer, as well as current treatments to prevent recurrence in women with HER2+ disease, and the issues presented by recent clinical trials of the HER dimerization inhibitor pertuzumab and the oral kinase inhibitor neratinib.

Related Links:
Enrolling Clinical Trials: Proton Radiotherapy for Accelerated Partial Breast Irradiation in Stage 0, I & II Breast Cancer
Dr Fox's Penn Medicine Profile
Dr Fox's Doximity Profile


February 13, 2018

Created by

Penn Physician VideoLink